Precision medicine for the world's highest-burden diseases.
A Singapore-based biomedical platform advancing four priority programs — HIV, HPV, glioblastoma, and rapid TB diagnostics — built on engineered immune therapies and AI-guided design.
A focused biomedical company.
MACRO HRD develops engineered immune therapies and AI-guided therapeutic design for diseases of major global burden — translating advanced science into clinical programs through partnerships with leading research institutions.
Our work is organized around four active programs and a set of enabling platforms. We pair engineered immune-cell and antibody science with a decision-intelligence layer that guides design and monitors safety — so that each program advances on evidence, not on hope.
Four programs, actively advancing.
Our focus is concentrated where the global disease burden is greatest and our science is most ready to translate.
An integrated therapeutic approach combining tri-specific antibodies, engineered immune effectors, and AI-guided coordination — aimed at durable viral control without lifelong therapy.
Immune-targeting therapeutic design for cervical cancer prevention, with mucosal delivery at the primary site of transmission — built for the populations carrying most of the burden.
An immune-based approach to glioblastoma engineered to cross the blood-brain barrier and activate anti-tumor response — advanced with a multi-institutional clinical and research network.
Next-generation tuberculosis diagnostic technology engineered for point-of-care public health deployment in high-burden regions — closing the gap between infection and treatment.
Beyond these four, MACRO HRD maintains a broader platform and pipeline of enabling technologies.
See the full pipeline →Guided by GEDM-3DQ —
our decision-intelligence layer.
Every program is supported by a proprietary AI decision engine that helps design therapeutics, sequence their delivery, and monitor safety signals across each patient's response. It is the common spine connecting our platforms — turning complex, multi-part therapies into coordinated, evidence-led programs.